ABVC BioPharma, Inc. (NASDAQ:ABVC) Sees Large Increase in Short Interest

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 186,200 shares, a growth of 34.8% from the October 15th total of 138,100 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 135,200 shares, the short-interest ratio is currently 1.4 days.

ABVC BioPharma Trading Up 2.9 %

ABVC stock opened at $0.54 on Thursday. The business’s fifty day moving average price is $0.62 and its 200 day moving average price is $0.76. ABVC BioPharma has a 12-month low of $0.41 and a 12-month high of $2.45. The company has a market capitalization of $6.64 million, a PE ratio of -0.32 and a beta of 0.82.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.12 million during the quarter. ABVC BioPharma had a negative net margin of 8,363.97% and a negative return on equity of 139.97%.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.